We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+52.1%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.24B
AUM Growth
+$511M
Cap. Flow
-$50.3M
Cap. Flow %
-2.25%
Top 10 Hldgs %
66.48%
Holding
69
New
5
Increased
9
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$92.4M
2
ALGS icon
Aligos Therapeutics
ALGS
+$69.1M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$58.1M
4
TXG icon
10x Genomics
TXG
+$8.56M
5
ZLAB icon
Zai Lab
ZLAB
+$5.38M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$32.1M
2
ARWR icon
Arrowhead Research
ARWR
+$23.8M
3
SAGE
Sage Therapeutics
SAGE
+$21.6M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$21.6M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.89%
2 Financials 5.49%
3 Materials 3.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$269M
$364M 16.23%
4,220,048
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$300M 13.38%
1,797,745
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$164M 7.31%
4,534,341
– –
TARS icon
4
Tarsus Pharmaceuticals
TARS
$2.61B
$134M 5.99%
+3,245,035
New +$92.4M
NFH
5
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$123M 5.49%
14,300,000
– –
ALGS icon
6
Aligos Therapeutics
ALGS
$26.1M
$98.1M 4.38%
+141,881
New +$69.1M
GTH
7
DELISTED
Genetron Holdings Limited ADS
GTH
$88.8M 3.96%
2,113,287
– –
AMRS
8
DELISTED
Amyris Inc.
AMRS
$81.3M 3.63%
13,161,847
+2,933
+0% +$9.38K
LEGN icon
9
Legend Biotech
LEGN
$3.69B
$77.6M 3.46%
2,755,007
-575,262
-17% -$16.6M
OLMA icon
10
Olema Pharmaceuticals
OLMA
$1B
$59.6M 2.66%
+1,238,575
New +$58.1M
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$41.2M 1.84%
5,966,527
– –
SVA
12
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 1.7%
5,900,000
– –
PASG icon
13
Passage Bio
PASG
$14.3M
$38M 1.7%
74,352
-35,221
-32% -$14.1M
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.88B
$33M 1.47%
2,335,889
+72,119
+3% +$1M
NKTX icon
15
Nkarta
NKTX
$161M
$31.5M 1.41%
512,225
– –
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$30.7M 1.37%
1,618,296
+141,500
+10% +$2.43M
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$30.7M 1.37%
1,917,074
– –
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.53B
$24.4M 1.09%
867,170
-246,095
-22% -$6.03M
KDMN
19
DELISTED
Kadmon Holdings, Inc.
KDMN
$24.1M 1.08%
5,817,459
+526,123
+10% +$2.08M
ZLAB icon
20
Zai Lab
ZLAB
$2.11B
$23.7M 1.06%
175,000
+52,893
+43% +$5.38M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$23.6M 1.05%
3,526,093
– –
CLDX icon
22
Celldex Therapeutics
CLDX
$2.79B
$22.6M 1.01%
1,291,875
-430,625
-25% -$7.75M
EPIX
23
DELISTED
ESSA Pharma
EPIX
$22.6M 1.01%
1,893,907
+377,042
+25% +$2.65M
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$22M 0.98%
59,709
– –
VRNA
25
DELISTED
Verona Pharma
VRNA
$21.3M 0.95%
3,048,507
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Vivo Capital held 69 positions worth $2.24B, up 30% from $1.73B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital's Q4 2020 filing shows 5 new, 9 increased, 19 reduced and 10 closed positions. Its largest new stake was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M. The largest sale was Immunovant, an estimated $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q4 2020 buy was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M.
  • Vivo Capital added most to Zai Lab in Q4 2020, an estimated $5.38M increase.
  • Vivo Capital's biggest Q4 2020 reduction was Immunovant, cutting an estimated $32.1M.
  • Vivo Capital fully exited Sage Therapeutics in Q4 2020, selling an estimated $21.6M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.24B portfolio in Q4 2020.
  • Vivo Capital opened 5 new positions and closed 10 in Q4 2020.
  • Vivo Capital's portfolio value rose 30% quarter-over-quarter to $2.24B.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.